At Photonic Pharma LLC, we focus on the early phase of drug development - Lead Discovery - using a game-changing technology platform that combines breakthroughs in fluorescence biosensor engineering and fluorescence lifetime detection in living cells. Thus we achieve a dramatic 30-fold increase in the precision of high-throughput screening of small-molecule libraries, with the potential to transform the productivity of pharmaceutical development.
We partner with industrial and academic collaborators, applying our proprietary advancements in structure-based drug-screening technology, to discover novel small-molecule effectors of therapeutically important protein targets. We have assembled a robust and highly integrated network of techniques, concepts, facilities and collaborators to address a wide range of therapeutic goals.
May 30, 2017
Photonic Pharma LLC is honored by its selection as a semifinalist in the 2017 MN Cup startup competition. This is the second year that Photonic has earned this recognition. MN Cup is the nation's largest statewide new venture competition. Photonic Pharma is one of ten semifinalists competing in the Life Science/Health IT division, and will go on to compete for a share of the record $450,000 in total prize money. Semi finalists also receive mentoring, training, and support to help advance their entrepreneurial ideas.
April 28, 2017
Photonic Pharma was a finalist and presented at the Walleye Tank Life Sciences Pitch Competition.
April 18, 2017
Photonic Pharma presented as one of the 40 "Best University Startups 2017" at the NCET2 University Startups Conference and Demo Day in Washington D.C.
For more information, visit the Photonic Pharma News tab.